Your Premium Trade Alert 9/1 (Ticker: ABVC) This Stock Is Surging Right Now

Premium Alert For 9/1 (Ticker: ABVC) This Stock Is Surging In Pre-Market! Hi there, This is Kevin Vander with "10XProTrader" delivering your premium alert for 9/1 is ABVC BioPharma Inc. (NASDAQ: ABVC). This stock is surging in pre-market this morning from huge news just released today. I urge you to read everything below right away. ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments FREMONT, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has filed new PCT (Patent Cooperation Treaty) applications in connection with its medicines that treat major depressive disorder (MDD) and Attention-Deficit Hyperactivity Disorder (ADHD). The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). PDC-1421 is the active ingredient for both the company's MDD and ADHD drugs. A recently completed Phase II Part II clinical study for ABVC's MDD medicine was a randomized, double-blind, placebo-controlled, multi-center trial, involving 60 adult patients with confirmed moderate to severe MDD who were treated with PDC-1421 three times a day for six weeks. PDC-1421 met the pre-specified primary endpoint by demonstrating a highly significant 13.2-point reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score by Intention-To-Treat (ITT) analysis, averaged over the 6-week treatment period (overall treatment effect) from baseline, as compared to 9.2-point reduction of the placebo group. By Per-Protocol (PP) analysis, PDC-1421 showed a dose dependent efficacy toward MDD in which high dose (2 x 380 mg) gave 13.4-point reduction in MADRS total score from baseline and low dose (380 mg) gave 10.4-point reduction as compared to 8.6 in the placebo group. The patients exhibited no severe adverse events. "We believe that the PCT filings, which provide quick entries to PCT contracting countries, such as China, Japan and European Union, can facilitate the global IP protection of our important MDD and ADHD products," said Dr. Howard Doong, ABVC BioPharma chief executive officer. "The PCT's and subsequent national phase applications, when granted, can extend our product's global market exclusivity to 2040~2041." Dr. Doong emphasized the importance of ABVC BioPharma's focus on botanical sourcing in drug development. "Our clinical trials continue to demonstrate that medicines derived from plants have significant therapeutic benefits with few - if any - side effects in treating serious medical conditions." About ABVC BioPharma ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). For Vitargus®, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe. I will be following up with you on this trade idea shortly. Yours for bigger profits, more often,

Kevin Vander CEO Founder 10XProTrader Investment Research From time to time your free 10XProTrader newsletter subscription is supplemented by paid sponsorships, like the one above. Please read all disclaimers. Rest assured that your information was not shared with this sponsor. Please note that 10XProTrader has not independently reviewed the validity of the claims or statements contained within this sponsorship, and we are not responsible for any errors or omissions. We have NOT been compensated for LWAC. Never invest in a security or idea featured on our site or in our emails unless you can afford to lose your entire investment. We are not registered investment advisors or brokers/dealers and we do not purport to be. We make no representations, warranties or guarantees as to the accuracy or completeness of the content featured on our site or in our emails. Furthermore, the article authors and contributors featured on this site may own securities mentioned in their articles and not disclose this information. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company. 10XProTrader does not endorse any investing or trading products or newsletters advertised in this email or on our web site. Please be sure to read our Terms & Conditions, Disclaimer and Privacy Policy.

10XProTrader, 99 Wall Street, New York, New York 10005, United States You may unsubscribe or change your contact details at any time.